Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft Model

Fig. 2

Toxicity study in HN12 tumor xenografted nude mice. Male mice bearing subcutaneous tumors were treated with excipient only IV (O; n = 6), 150 µg/kg/day IV (♦; n = 8), 200 µg/kg/day IV (▲; n = 4), or 300 µg/kg/day CI (■; n = 8) of IL13-PE38QQR from day 4 to 10 (7 days). (A) Anti-tumor activity of IL-13 toxin is shown. Bars represent the SD. (B) survival rates are expressed as percentage of surviving mice compared with control. Experiments were performed twice with similar results.

Back to article page

Molecular Medicine

ISSN: 1528-3658